850103P
Avanti
17:1 Lyso PI
1-(10Z-heptadecenoyl)-2-hydroxy-sn-glycero-3-phospho-(1′-myo-inositol) (ammonium salt), powder
Synonyme(s) :
PI(17:1(10Z)/0:0); 110718
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Formule empirique (notation de Hill):
C26H52NO12P
Numéro CAS:
Poids moléculaire :
601.66
Code UNSPSC :
51191904
Nomenclature NACRES :
NA.25
Produits recommandés
![17:1 Lyso PS 1-(10Z-heptadecenoyl)-2-hydroxy-sn-glycero-3-[phospho-L-serine] (sodium salt), powder](/deepweb/assets/sigmaaldrich/product/structures/229/750/c333733e-eb96-4303-8bce-4f5ffb1bb637/640/c333733e-eb96-4303-8bce-4f5ffb1bb637.png)
![14:0 Cardiolipin (ammonium salt) 1′,3′-bis[1,2-dimyristoyl-sn-glycero-3-phospho]-glycerol (ammonium salt), chloroform](/deepweb/assets/sigmaaldrich/product/images/430/612/0f445fb1-937a-4275-bc4f-007d8a8a3328/640/0f445fb1-937a-4275-bc4f-007d8a8a3328.jpg)
Pureté
>99% (LPI; may contain up to 10% of the 2-LPI isomer, TLC)
Forme
powder
Conditionnement
pkg of 1 × 100 μg (with stopper and crimp cap (850103P-100ug))
pkg of 1 × 500 μg (with stopper and crimp cap (850103P-500ug))
Fabricant/nom de marque
Avanti Research™ - A Croda Brand 850103P
Type de lipide
phosphoglycerides
Conditions d'expédition
dry ice
Température de stockage
−20°C
Chaîne SMILES
[H][C@@](COP([O-])(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O)=O)(O)COC(CCCCCCCC/C=C\CCCCCC)=O.[NH4+]
Catégories apparentées
Description générale
Lysophosphatidylinositol (LPI), a degradation product of phosphatidylinositol (PI) is a lysophospholipid subspecies, which carries inositol in its head group.
Application
17:1 Lyso PI (1-(10Z-heptadecenoyl)-2-hydroxy-sn-glycero-3-phospho-(1′-myo-inositol)) has been used as an internal standard in LC-MS of mice brain lipidomic analysis. It may be used as internal standard in for the analysis of lysophosphatidylinositols (LPIs) in mice using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry (HPLC/ESI-MS) and in the quantification of lysoPI (LPI) in livers of chronic high-fat diet (HFD)-fed WT and KO mice using liquid chromatography with tandem mass spectrometry (LC-MS-MS) system.
Actions biochimiques/physiologiques
Increased circulating levels of L-alpha-lysophosphatidylinositol (LPI) are associated with cancer and LPI is a potent ligand for the G-protein-coupled receptor GPR55.
Lysophosphatidylinositol (LPI) serve as a bioactive lysophospholipid mediator. It favors mitogenic activity in quiescent fibroblasts. LPI has the ability to block hippocampal neuronal death in conditions of forebrain ischemia.
Conditionnement
2 mL Amber Serum Vial with Stopper and Crimp Cap (850103P-100ug)
2 mL Amber Serum Vial with Stopper and Crimp Cap (850103P-500ug)
Informations légales
Avanti Research is a trademark of Avanti Polar Lipids, LLC
Souvent commandé avec ce produit
Réf. du produit
Description
Tarif
Code de la classe de stockage
11 - Combustible Solids
Classe de danger pour l'eau (WGK)
WGK 3
Point d'éclair (°F)
No data available
Point d'éclair (°C)
No data available
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Les clients ont également consulté
Ann-Christin Otto et al.
Biochimica et biophysica acta. Molecular and cell biology of lipids, 1864(5), 662-676 (2019-02-09)
A defect of hepatic remodeling of phospholipids (PL) is seen in non-alcoholic fatty liver disease and steatohepatitis (NASH) indicating pivotal role of PL metabolism in this disease. The deletion of group VIA calcium-independent phospholipase A2 (iPla2β) protects ob/ob mice from
Julien Masquelier et al.
Journal of pharmaceutical and biomedical analysis, 126, 132-140 (2016-05-22)
Increasing evidence suggests that lysophosphatidylinositols (LPIs), a subspecies of lysophospholipids, are important endogenous mediators. Although LPIs long remained among the less studied lysophospholipids, the identification of GPR55 as their molecular target sparked a renewed interest in the study of these
Atsushi Yamashita et al.
Prostaglandins & other lipid mediators, 107, 103-116 (2013-05-30)
Lysophosphatidylinositol (LPI) is a subspecies of lysophospholipid and is assumed to be not only a degradation product of phosphatidylinositol (PI), but also a bioactive lysophospholipid mediator. However, not much attention has been directed toward LPI compared to lysophosphatidic acid (LPA)
Tsukasa Yagi et al.
Cancers, 12(1) (2020-01-01)
Ovarian cancer remains a highly lethal disease due to its late clinical presentation and lack of reliable early biomarkers. Protein-based diagnostic markers have presented limitations in identifying ovarian cancer. We tested the potential of phospholipids as markers of ovarian cancer
Jordon M Inloes et al.
Biochemistry, 57(39), 5759-5767 (2018-09-18)
Deleterious mutations in the serine hydrolase DDHD domain containing 1 (DDHD1) cause the SPG28 subtype of the neurological disease hereditary spastic paraplegia (HSP), which is characterized by axonal neuropathy and gait impairments. DDHD1 has been shown to display PLA1-type phospholipase
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique